June 3 would have been an excellent day to channel your inner Warren Buffett and buy CSL Ltd (ASX: CSL) shares.

Of the many investment quotes Buffett is famous for, perhaps the best known is, “Be greedy when others are fearful.”

Indeed, on 3 June, a lot of investors were fearful about buying the S&P/ASX 200 Index (ASX: XJO) biotech giant, after it closed at a more than nine-year low.

Why did CSL shares crash to a multi-year low?

The CSL share price decline began in mid-2024 and ran for roughly two years.

Over this time the company issued a number of earnings downgrades, partly driven by lower than forecast plasma demand.

Vaccine uptakes in the United States also slumped, right about when management announced their plan to spin off the CSL Seqirus segment, its influenza vaccine business, into a separate ASX-listed company. (That plan remains on hold at the moment.)

Investors also reacted negatively to former CSL CEO Paul McKenzie’s unexpected exit in February this year.

Which brings us back to the closing bell on June 3, when you could have picked up CSL for just $92.24 a share.

Investing $10,000 into the ASX 200 healthcare share

If you’d embraced your inner Warren Buffett and invested $10,000 in the ASX 200 biotech stock on 3 June, you could have picked up 108 shares with a bit of pocket money left over.

On Tuesday, CSL shares were trading for $171.66 apiece. And if you held the stock through to market close, you’d also have received the final CSL dividend of $2.277 a share.

The stock is trading ex-dividend today.

So, if we add that passive income payout back into the recent share price, then the accumulated value of the shares you picked up for $92.24 on June 3 works out to (a rounded) $173.94 each.

Meaning the 108 shares you acquired for $10,000 just over three months ago would be worth $18,786 today.

Or a gain of 87.9%.

What’s sent the CSL shares rocketing?

By 17 August, shares in the ASX 200 healthcare stock had recovered to $134.60 as investors began to bet on the success of the company’s ‘reset’ process.

Then on 18 August, CSL shares rocketed 17.3% following the release of the company’s full-year FY 2026 results.

While revenue declined 1% year on year and CSL reported a net loss after tax of US$2.6 billion, the company forecast steady revenue in FY 2027 and underlying NPAT growth of around 5%.

“FY26 has been a year of reset. We have taken decisive action and created a clear path to return to sustainable growth,” CSL interim CEO Gordon Naylor said on the day of the results release.

The post $10,000 invested in CSL shares in June is now worth… appeared first on The Motley Fool Australia.

More reading

• Forget CSL shares. 3 ASX healthcare stocks with bigger upside
• If I invest $10,000 in CSL shares, what passive income will I earn in FY27?
• UBS names its 10 top ASX picks for the next 3-6 months
• Are CSL shares still cheap after almost doubling since June?
• CSL led the ASX healthcare shares rebound. Can it continue?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares have surged 32% over the past month after stronger-than-expected plasma product sales. But with the rally potentially priced in, analysts see better value elsewhere in healthcare.

CSL shares are now trading around $174.80, above the average broker price target. Macquarie has a neutral rating and a target of just over $133, while UBS is more bullish at $181 and Morgan Stanley has a $172 target.

So, where could investors look instead?

Pro Medicus Ltd (ASX: PME)

Pro Medicus shares have endured a brutal 12 months, falling around 43%. But unlike CSL shares, the sell-off hasn’t been accompanied by a deterioration in the company’s underlying growth.

FY26 revenue increased 22.9% to $261.7 million, while underlying EBIT and NPAT climbed 24.4% and 24.1%, respectively.

Its Visage imaging software is already used by major healthcare systems across North America, yet management estimates it has captured only around 11% of the US market. That leaves plenty of room to grow.

Citi has a buy rating and $225 target, implying around 33% upside. Bell Potter is also bullish, with a $226 target, while Barrenjoey has a $210 target. JPMorgan is more cautious with a hold rating and $211 target.

ResMed Inc (ASX: RMD)

ResMed shares have bounced around 25% from their multi-year low in June, but remain down roughly 25% over 12 months. That’s a steeper decline than CSL shares, which still fell 18% over the same period despite their recent rebound.

The sell-off reflected broader pressure on healthcare shares, alongside macroeconomic uncertainty, inflation and cost-of-living concerns. A soft third-quarter update in May added to the pressure.

However, ResMed subsequently delivered a stronger fourth-quarter result, helping restore investor confidence.

The sleep-disorder specialist continues to deliver healthy revenue growth, expanding margins and strong free cash flow. Its third-quarter revenue rose 11% to US$1.4 billion, driven by demand for sleep devices, masks and accessories.

Most brokers rate ResMed shares buy or strong buy. The highest price target of $45.90 implies potential upside of around 46%.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix Pharmaceuticals operates in a highly specialised healthcare niche: radiopharmaceuticals. Its products combine radioactive isotopes with targeted diagnostics and therapies, helping doctors detect and treat diseases such as cancer with greater precision.

That creates significant barriers to entry and gives Telix shares an interesting growth profile that differs from CSL shares.

In August, Telix reported a 22% year-on-year increase in revenue to US$477 million, putting it towards the upper end of its FY26 guidance.

Brokers are increasingly bullish, with 13 of 16 analysts rating Telix shares buy or strong buy. The average $25.29 target implies roughly 53% upside from $16.50, while the most bullish forecast points to more than 85% potential upside.

For investors looking beyond CSL shares, these three healthcare names could offer considerably more upside.

The post Forget CSL shares. 3 ASX healthcare stocks with bigger upside appeared first on The Motley Fool Australia.

More reading

• $10,000 invested in CSL shares in June is now worth…
• 6 ASX shares tipped by brokers to rise 34% to 87%
• If I invest $10,000 in CSL shares, what passive income will I earn in FY27?
• UBS names its 10 top ASX picks for the next 3-6 months
• Are CSL shares still cheap after almost doubling since June?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Pro Medicus, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The All Ordinaries Index (ASX: XAO) has slid lower over the past month as ASX shares are hit by falling investor confidence, concerns about inflation, and interest rate hike fears.

At the time of writing, the All Ords Index is down around 3%.

But at times when confidence is sliding, it’s important to pinpoint shares which could outperform going forward. 

Here are two ASX shares that brokers are tipping to outperform the index over the next 12 months. And they’re forecast to grow by up to 42%.

Superloop Ltd (ASX: SLC)

Superloop is an Australian-based fixed-line internet service provider. It provides broadband services to consumers and businesses across the Asia Pacific region, and wholesale solutions to other downstream internet services entities. 

Its services include Wi-Fi management, mobile services, and National Broadband Network products. The company owns an extensive fiber network and is also a part-owner of the Indigo subsea cable. 

The telco has rapidly expanded in recent years with several large acquisitions. These include Lightning Broadband (an internet service provider) in May 2026, Uecomm (a fiber infrastructure) in 2024, and Exetel (an internet retailer) in 2021.

The company also posted an impressive FY26 earnings result last month. It reported a 21.6% increase in reported revenue, a 33.1% increase in underlying EBITDA, and NPAT of $17.5 million.

At the time of writing, Superloop shares are up around 0.5% for the day to $2.75. For the year-to-date the shares have increased around 8%, but the stock is about 12% lower than 12 months ago. 

Going forward, analysts are very bullish about Superloop’s potential for growth in FY27. Market Index data shows all brokers have a strong buy rating on the ASX telco shares. And the $3.90 average target price implies an upside of around 42%, at the time of writing.

Universal Store Holdings Ltd (ASX: UNI)

Universal Store is an Australian retailer specialising in trend-led and casual men’s and women’s fashion, shoes, accessories, lifestyle, and gifting. 

The company owns a portfolio of popular premium fashion brands like Champion, Perfect Stranger, Tommy Jeans, Kiss Chacey, Thrills, Barney Cools, and others.

The ASX consumer discretionary shares crashed to a two year low in May after a deterioration in trading conditions saw investors quickly sell up their shares. 

The update followed a broad decline in discretionary shares, as geopolitical uncertainty and inflation concerns prompted an investor rotation towards more defensive sectors.

At the time of writing, Universal Store shares are down around 2% and changing hands at $7.62 each. For the year-to-date, the shares are down around 6% and 13% lower than 12 months ago.

But the experts appear to be confident that we’ll see a turnaround in the coming months. Market Index data shows all brokers have a strong buy rating on the shares, and the $9.67 average target price implies a potential 25% upside at the time of writing.

The post 2 ASX shares tipped by brokers to return 25% and 42% appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation for $3,000 in weekly passive income?
• 3 stellar ASX dividend stocks to supplement your superannuation 
• Why investors should be targeting ASX mid-caps and ASX small-caps after earnings season: Expert
• 3 top ASX dividend shares to buy in September
• 2 ASX dividend shares with yields above 7%

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Universal Store. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.